Article
A Single Institution Experience of Bortezomib for GVHD in a Pediatric HSCT Population
2024-01-31
Abstract excerpt
Acute graft versus host disease (aGvHD) remains one of the most serious complications, occurring in about 30-70%, of allogeneic hematopoietic stem cell transplantation (HSCT) recipients. While about 40-60% of these recipients will respond to steroids as first line, there is no consensus on second line agents. The management of steroid-refractory (SR) and steroid dependent (SD) GVHD after HSCT continues to be chall...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 4028153c-62ed-55ef-b2fa-a64371e1cbaa
- DOI
- 10.22541/au.170668419.92045549/v1
